India, Oct. 23 -- Bristol Myers Squibb (BMY) presented interim results from the Phase 1 Breakfree-2 study of investigational zolacabtagene autoleucel (zola-cel) in patients with highly active relapsing and progressive multiple sclerosis (MS) at MSToronto 2026.
Zola-cel, also known as BMS-986353, is an investigational autologous CD19-directed CAR T-cell therapy designed to deplete B cells and potentially reset the immune system.
The study included 66 patients, comprising 30 with highly active relapsing MS and 36 with progressive MS. Patients had ongoing disease activity or worsening disability despite treatment and had received a median of two prior disease-modifying therapies.
At the latest follow-up, all 60 patients treated at dose leve...